Do TNF inhibitors effect outcomes in pregnant women with IBD?

Anti-tumor necrosis factor (anti-TNF), including infliximab and adalimumab, have been increasingly used in clinical practice to manage inflammatory bowel disease (IBD) in pregnant women. A recent study aimed to determine which biologics are better for these patients.

This systematic review and meta-analysis included 8 studies including 527 pregnant women with IBD to analyze adverse pregnancy outcomes.

Of those included in the study, 343 were treated with infliximab, and 184 were treated with adalimumab.

There were no differences in adverse pregnancy outcomes, including congenital malformations and spontaneous abortion, between infliximab and adalimumab.

Reference
Wang H, Hu Y, Chen F, et al. Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis. BMC Pregnancy Childbirth. 2022;22(1):854. doi: 10.1186/s12884-022-05191-z. PMID: 36402978.